ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer

blonca9
Jun 1
1 min read

He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared to one product that is already on the market.

Recent Posts

See All

EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T

EHA 2025: The CEO of Ascentage Pharma, which had its U.S. IPO earlier this year, introduces us to the company and discusses BCR-ABL, Bcl-2, and EED targeting programs

EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight